Literature DB >> 22440873

Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.

Jose A Carrillo1, Claudia A Munoz.   

Abstract

Irinotecan, cisplatin, and nitrosoureas have a long history of use in brain tumors, with demonstrated efficacy in the adjuvant treatment of malignant gliomas. In the era of temozolomide with concurrent radiotherapy given as the standard of care, their use has shifted to treatment at progression or recurrence. Now with the widespread use of bevacizumab in the recurrent setting, irinotecan and other chemotherapies are seeing increased use in combination with bevacizumab and alone in the recurrent setting. The activity of these chemotherapeutic agents in brain tumors will likely ensure a place in the armamentarium of neuro-oncologists for many years. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22440873     DOI: 10.1016/j.nec.2012.01.005

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  4 in total

Review 1.  Treatments against Polymorphosal discrepancies in Glioblastoma Multiforme.

Authors:  Swastika Maitra; Biswajit Chakraborty; Sumira Malik; Athanasios Alexiou; Nobendu Mukerjee; Subhradeep Roy; Shaswata Modak; Mohammad Mehedi Hasan; Arabinda Ghosh; Asmita Ghosh; Mohammad Amjad Kamal; Abhijit Dey; Ghulam Md Ashraf; Md Habibur Rahman; Badrah S Alghamdi; Adel Mohammad Abuzenadah
Journal:  Metab Brain Dis       Date:  2022-09-23       Impact factor: 3.655

2.  Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme.

Authors:  David Fortin; Pierre-Aurèle Morin; Francois Belzile; David Mathieu; Francois-Michel Paré
Journal:  J Neurooncol       Date:  2014-06-20       Impact factor: 4.130

Review 3.  Research progress of anti-glioma chemotherapeutic drugs (Review).

Authors:  Yi-Shu Zhou; Wei Wang; Na Chen; Li-Cui Wang; Jin-Bai Huang
Journal:  Oncol Rep       Date:  2022-04-01       Impact factor: 3.906

Review 4.  Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

Authors:  Daniel Ruiz-Molina; Xiaoman Mao; Paula Alfonso-Triguero; Julia Lorenzo; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Fernando Novio
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.